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Evaluation of transcriptional changes in the striatum may be an effective approach to understanding the
natural history of changes in expression contributing to the pathogenesis of Huntington disease (HD). We
have performed genome-wide expression profiling of the YAC128 transgenic mouse model of HD at 12 and
24 months of age using two platforms in parallel: Affymetrix and Illumina. The data from these two powerful
platforms were integrated to create a combined rank list, thereby revealing the identity of additional genes
that proved to be differentially expressed between YAC128 and control mice. Using this approach, we ident-
ified 13 genes to be differentially expressed between YAC128 and controls which were validated by quanti-
tative real-time PCR in independent cohorts of animals. In addition, we analyzed additional time points
relevant to disease pathology: 3, 6 and 9 months of age. Here we present data showing the evolution of
changes in the expression of selected genes: Wt1, Pcdh20 and Actn2 RNA levels change as early as 3
months of age, whereas Gsg1l, Sfmbt2, Acy3, Polr2a and Ppp1r9a RNA expression levels are affected
later, at 12 and 24 months of age. We also analyzed the expression of these 13 genes in human HD and control
brain, thereby revealing changes in SLC45A3, PCDH20, ACTN2, DDAH1 and PPP1R9A RNA expression.
Further study of these genes may unravel novel pathways contributing to HD pathogenesis. DDBJ/EMBL/
GenBank accession no: GSE19677
INTRODUCTION
Huntington disease (HD) is a neurological disorder character-
ized by early selective neuronal cell death in striatum and
cortex caused by mutations in the human HTT gene (1). Expan-
sion of the CAG tract in exon 1 of the HTT gene leads to an
abnormally long polyglutamine tract in huntingtin, a protein
ubiquitously expressed throughout the body and brain. Neuro-
pathological features are observed in the neostriatum, globus
pallidus and cerebral cortex with a selective loss of the large
pyramidal neurons in cortical layers III, IV and VI (2,3).
Evidence derived from cellular and animal models of HD
has identified a number of potential mechanisms by which
polyglutamine-expanded huntingtin protein results in neuronal
cell death. These include disruption of the axonal transport,
mitochondrial dysfunction, imbalance in calcium homeostasis
and excitotoxicity, altered proteolysis, impairment of the ubi-
quitin proteosome system and transcriptional alterations (4,5).
Specific changes in mRNA expression have been described in
human postmortem brains and in cellular and mouse models of
HD. Down-regulation of dopamine D1 and D2 receptors,
enkephalin, substance P (6–8) and several striatal-enriched
genes have been found altered in postmortem caudate
samples from HD cases using quantitative real-time PCR
analysis (qPCR) (9). Microarray studies performed on
human HD brain samples (grade 0–2) have demonstrated
Towhom correspondence should be addressed at: Centre forMolecularMedicine and Therapeutics, Department ofMedical Genetics, University of British
Columbia, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4. Tel: þ1 6048753801; Fax: þ1 6048753840; Email: bleavitt@cmmt.ubc.ca
# The Author 2010. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
Human Molecular Genetics, 2010, Vol. 19, No. 8 1438–1452
doi:10.1093/hmg/ddq018
Advance Access published on January 20, 2010
that the caudate nucleus manifests the greatest number and
magnitude of transcriptional changes, followed by motor
cortex and then cerebellum, with no significant change detect-
able in prefrontal association cortex (10).
There is concordance of striatal-enriched genes differen-
tially expressed in HD mouse models with gene expression
changes identified in human microarray studies (11). For
example, several of the genes showing the greatest magnitude
of changes, such as the cannabinoid CB1 receptor, dopamine
D1 receptor and enkephalin genes, have also been identified
as differentially expressed in expression profiling studies of
transgenic mice (10–12). Also, a considerable number of
Ca2þ-binding and Ca2þ, Kþ and Naþ channel mRNAs are
down-regulated in humans in concordance with previous
observations in the R6/2 transgenic mouse model (13–15).
The YAC128 mouse model of HD expresses full-length
human mutant huntingtin with 128 glutamines from a
yeast artificial chromosome (YAC) (16,17). This mouse
model expresses full-length huntingtin under the endogenous
human huntingtin promoter and spans both up- and downstream
regulatory regions. YAC128 mice display disease progression
over time with both neuropathological and behavioral deficits
similar to human disease. Initially, YAC128 mice exhibit be-
havioral changes with a hyperkinetic phenotype and rotarod
deficits at 3 months of age (18). YAC128 mice display
several neuropathological changes characteristic of HD with a
significant decrease in brain weight and striatal volume
observed at 8 months (19), and a selective neuronal loss in stria-
tum and cortex at 12 months of age (18). The fact that YAC128
transgenic mice display early onset cognitive and motor deficits
with selective neuropathology recapitulating key features of
human disease makes this mouse model useful for studies into
disease pathogenesis.
The majority of genome-wide expression studies performed
including studies on different HD mouse models have employed
the Affymetrix Gene chip platform when studying gene
expression changes. More recent technologies, such as the
Illumina Bead array platform, are now also widely used for this
kind of analysis. Affymetrix arrays are produced by in situ syn-
thesis of 25-mer oligonucleotides with multiple probes for each
gene. The Affymetrix arrays contain one-base mismatch probes
as controls for cross-hybridization. In contrast, the Illumina
Bead arrays are based on self-assembly of 50-mer-long oligonu-
cleotides to microbeads. Bead arrays contain 30 copies of the
same oligonucleotide as an internal technical replication, which
Affymetrix arrays lack. We employed both platforms to increase
the power of the gene expression profile analysis of the YAC128
and controls with the ultimate goal of studying transcriptional
alterations in striatum and identifying genes of importance for
disease pathogenesis.
In this study, we present evidence for both early and late
transcriptional changes of genes in the striatum that we
initially identified by genome-wide expression profiling of
the YAC128 mouse model of HD using the Affymetrix and
Illumina platforms. As our experiments were designed to
analyze both platforms in parallel as a validation tool, we
first analyzed the same striatal mRNA separately across both
platforms. We identified modest transcriptional changes on
the individual platforms. This prompted us to an alternative
approach, to combine the results from the Affymetrix and
Illumina platforms to create combined rank lists. We show
that combining data sets obtained from two powerful indepen-
dent platforms revealed the identity of additional genes that
were differentially expressed between YAC128 and control
mice at 12 and 24 months of age. To further validate our
results, we analyzed the top 10 genes ranked from the Illumina,
Affymetrix and the combined rank lists, respectively, by apply-
ing the more sensitive qPCR methodology. For genes validated
to be differentially expressed, we also analyzed earlier time
points: 3-, 6- and 9-month-old YAC128 mice and controls.
In summary, we have applied an unbiased approach to
combine results from two powerful expression array platforms
that identified a set of genes that showed a differential regu-
lation between YAC128 and controls. In total, we evaluated
expression of 13 genes at time points relevant to disease path-
ology. This analysis revealed several genes Wt1, Pcdh20 and
Actn2 that display transcriptional changes already at 3
months of age, early in the manifestation of the HD phenotype
of these mice. The expression of additional genes, Gsg1l,
Sfmbt2, Acy3, Polr2a and Ppp1r9a, was found to be altered
only at later time points. We examined the expression of
these genes in human HD caudate and controls and demon-
strated transcriptional changes in SLC45A3, PCDH20,
ACTN2, DDAH1 and PPP1R9A, validating the relevance of
these findings in mouse to the human disease. Further study
of these genes might elucidate novel disease mechanisms of
importance in HD.
RESULTS
Genome-wide expression profiling of 24-month-old
YAC128 mice and controls using Affymetrix
and Illumina platforms
We initially compared the transcriptional changes in the stria-
tum of 24-month-old YAC128 and wild-type littermate control
mice. YAC128 mice display a clear progression of disease
with age that correlates with the degree of selective neuronal
loss and neurodegeneration. There is an established correlation
between levels of mutant huntingtin, disease severity and
neuronal loss in YAC128 mice (20). We studied the gene
expression profiles of the same mRNA using two different
platforms: Illumina and Affymetrix (Supplementary Material,
Fig. S1). YAC128 mice showed both an up- (light yellow) and
down-regulation (dark brown) of genes compared with con-
trols. However, no genes were significantly different on
either platform after correction for multiple comparisons (21).
Calculating combined ranks from the Affymetrix and
Illumina profiles for 24-month-old YAC128 and controls
Gene expression studies using Affymetrix GeneChips and
Illumina Bead arrays have previously been compared side by
side with a high agreement for genes that were predicted to
be differentially expressed (22). We therefore examined our
genome-wide expression data to determine whether genes
had similar ranks on both platforms, taking into account that
48 000 probe sets are analyzed on the Illumina arrays and
45 000 probe sets are measured on the Affymetrix counterpart.
In order to focus on the very best candidate changes, we only
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considered the data for the top 100 genes on each platform
(ranked by probability of differential expression). We found
both concordant as well as discordant predicted changes in
expression between the two platforms. Discordant predictions
may be due in part to low expression levels of some genes or
the fact that the specific probes employed in the two platforms
assay different splice variants or transcripts of a gene (23).
While our experiments were designed to analyze both plat-
forms in parallel as a validation tool, the modest transcrip-
tional changes observed with both platforms prompted us to
attempt an alternative approach to identify differentially
expressed genes in YAC128 mice compared with controls.
We subsequently used the two data sets to create a combined
rank list. We calculated a combined rank for each gene by
averaging the individual ranks generated from the Affymetrix
and Illumina platforms (Supplementary Material, Table S1).
This approach incorporates a confirmatory identification of
differentially expressed genes. Furthermore, this approach
helped to elute genes of interest despite small sample sizes
and low magnitude of transcriptional changes in our experi-
mental setting. However, by implementing this approach, we
down-weighed false-positive changes, i.e. genes that were
ranked high on one platform, but not reproduced on the
other platform, would tend to be down-weighed.
Transcriptional changes identified in the top 10 genes from
Affymetrix and Illumina genome-wide expression profiling
We next decided to validate the separate findings from the
Illumina and Affymetrix results using qPCR. We assessed the
top 10 differentially expressed genes based on the Illumina
and Affymetrix results, respectively, on mRNAs from a new
cohort of 24-month-old YAC128 and control mice (Supplemen-
tary Material, Fig. S1). This analysis resulted in confirmation of
three genes out of 10 from the Illumina results to be differen-
tially expressed, i.e. Wilm’s tumor 1 homolog (Wt1), DAZ
interacting protein 1-like (Dzip1l) and Retrotransposon gag
domain containing 4 (Rgag4), where Wt1 was up-regulated,
and both Dzip1l and Rgag4 were down-regulated in YAC128
compared with controls (Supplementary Material, Fig. S2;
Table 1). Netrin G1 (Ntng1) showed a trend for up-regulation
in the YAC128 mice compared with controls that was not stat-
istically significant. The mRNAs for the RAB21 member of the
RAS oncogene family (Rab21), Docking protein 3 (Dok3),
Dopa decarboxylase (Ddc) and up-regulated during skeletal
muscle growth 5 (Usmg5) were not found to be differentially
expressed between YAC128 and controls in the qPCR analyses
(Supplementary Material, Fig. S2). Three different primer sets
were tested for olfactory receptor 1502 (Olfr1502) and fibronec-
tin type III domain containing 8 (Fndc8), but we were unable to
amplify and quantify these genes from striatal RNA.
Similar results obtained with four genes out of 10 detected
as differentially expressed based on the Affymetrix results
confirmed that differentially expressed RNAs comprised
Wt1, DNA damage inducible transcript 4-like (Ddit4l), germ
cell-specific gene 1-like protein (Gsg1l) and solute carrier
family 45, member 3 (Slc45a3; Supplementary Material,
Fig. S3; Table 1). In addition to Wt1, which was top ranked
in both the Illumina and Affymetrix rank results, Slc45a3
was also up-regulated, whereas Ddit4l and Gsg1l were
down-regulated in YAC128 compared with control mice.
DMPK also showed a non-statistically significant trend
towards down-regulation in YAC128 compared with controls.
Deleted in lymphocytic leukemia, 7 (Dleu7), spermatogenesis
associated 5 (Spata5), ectonucleoside triphosphate diphosphohy-
drolase 7 (Entpd7), GRP1-associated scaffold protein (Grasp)
and regulator of telomere elongation helicase 1 (Rtel1) were
not differentially expressed in YAC128 compared with controls
(Supplementary Material, Fig. S3).
Identification of additional genes from the combined rank
list validated as differentially expressed in YAC128
We next assessed the differential expression of the genes from
the created combined rank list for 24-month-old YAC128 and
control striatal mRNA samples. The qPCR analysis of the top
10 genes from the combined rank list showed differential
expression in YAC128 compared with controls for six out of
the 10 genes analyzed (Table 1). Wt1, Ntng1 and Ddit4l
were included in the top 10 for both Affymetrix and/or
Illumina and in the created combined rank list. Additional
genes from the combined rank list that were shown to be differ-
entially expressed were: Protocadherin 20 (Pcdh20), Scm-like
with four MBT domains protein 2 (Sfmbt2), Aspartoacylase 3
(Acy3) and Polymerase (RNA) II (DNA directed) polypeptide
A (Polr2a) (Supplementary Material, Fig. S4). All of these
genes were significantly up-regulated in YAC128 compared
with controls. There was no significant difference in gene
expression for Transducer of ERBB2 (Tob2), Pogo transposable
element with KRAB domain (Pogk) or HIV-1 Rev binding
protein-like (Hrbl) between YAC128 and controls at 24
months of age (Table 1; Supplementary Material, Fig. S4).
Transcriptional alterations revealed using the combined
rank strategy on 12-month-old YAC128 and controls
We next studied the YAC128 mice compared with controls at
the earlier 12-month time point. Both neuropathological and
Table 1. Summary of validated genes in YAC128 and control mice using
qPCR
24 months 24 months 24 months 12 months
Illumina Affymetrix Combined rank Combined rank
Wt1 Wt1 Wt1 Mllt10
Ntng1 Ddit4l Ntng1 Surf4
Rab21 DMPK Tob2 Actn2
Dzip1l Gsg1l Pcdh20 Foxj3
Dok3 Dleu7 Sfmbt2 Tnpo1
Olfr1502 Spata5 Pogk Ddah1
Fndc8 Entpd7 Acy3 N4bp1
Rgag4 Grasp Hrbl Wfdc1
Ddc Slc45a3 Polr2a Zfp371
Usmg5 Rtel1 Ddit4l Ppp1r9a
3/10 4/10 6/10 3/10
The top 10 genes from the Affymetrix, Illumina and the combined rank lists for
12 and 24 months were validated by qPCR in independent cohorts of YAC128
and control mice. Genes in bold were differentially expressed between
YAC128 and controls. We created combined rank lists for the 12- and
24-month data by averaging the individual ranks generated from the
Affymetrix and Illumina results for each target.
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behavioral abnormalities are established in the transgenic mice
at this time point. YAC128 mice display approximately 10–
15% striatal atrophy and 9% neuronal loss at 12 months of
age (24). We used the same approach as for the 24-month-old
mice to calculate a combined rank by averaging the ranks
obtained from the individual platforms (Supplementary
Material, Table S2). We again performed qPCR analyses of
the top 10 genes from the established combined rank list
using a new cohort of 12-month-old YAC128 and control
mice. Three out of 10 genes were validated to be differentially
expressed: a-actinin 2 (Actn2), dimethylarginine dimethylami-
nohydrolase 1 (Ddah1) and protein phosphatase 1, regulatory
(inhibitor) subunit 9A (Ppp1r9a) (Fig. S5; Table 1). Interest-
ingly, all three genes were down-regulated in YAC128 at 12
months of age. Myeloid/lymphoid leukemia 10 (Mllt10),
Surfeit 4 gene (Surf4), Forkhead box J3 (Foxj3), Transportin
1 (Tnpo1), Nedd4-binding protein 1 (N4bp1) and WAP for-
disulfide core domain protein 1 precursor (Wfdc1) were
not differentially expressed between YAC128 and controls
(Supplementary Material, Fig. S5). Three different primer
sets were tested for Zinc finger protein 371 (Zfp371), but we
were unable to amplify and quantify the expression of this
gene from mouse striatal RNA.
Time course analysis of differentially expressed genes
show both early and late changes in gene expression
To further characterize the change in expression of the genes
that were identified as differentially expressed at 12 or 24
months, we studied additional time points of relevance to
disease pathogenesis with regard to both early onset of behav-
ioral abnormalities and neuropathological changes. Taken
together, we analyzed the gene expression at 3, 6, 9, 12 and
24 months of age on mRNA from new cohorts of YAC128
and controls using qPCR for each target. Wt1 displayed
dynamic transcriptional changes over all five time points ana-
lyzed. Initially, YAC128 mice showed an up-regulation ofWt1
at 3 months of age (P ¼ 0.029, Mann–Whitney two-tailed
U-test) compared with controls (Fig. 1A). This, however,
reverted to similar transcript levels expressed in YAC128
and control mice at 6 months. YAC128 displayed a down-
regulation ofWt1 at 9 months of age (P ¼ 0.017), before a dis-
tinct 2- and 5-fold up-regulation was observed in YAC128
compared with controls at 12 (P ¼ 0.0025) and 24 months
(P ¼ 0.0012), respectively. YAC128 mice showed a continu-
ous down-regulation of Ddit4l (Fig. 1B) from 6 to 24
months of age, except for at 12 months when YAC128 and
Figure 1. Time course analysis of differentially expressed genes identified on the Affymetrix and Illumina platforms. We analyzed the top 10 genes from the
Affymetrix and Illumina results. YAC128 and wild-type littermate controls were analyzed at 3, 6, 9, 12 and 24 months of age by qPCR. We analyzed Wilm’s
tumor 1 homolog (Wt1), DNA damage-inducible transcript 4 like (Ddit4l), germ cell-specific gene 1-like protein (Gsg1l) and solute carrier family 45, member 3
(Slc45a3). YAC128 showed an up-regulation ofWt1 transcript levels at 3 months (P ¼ 0.029), 12 months (P ¼ 0.0025) and 24 months (P ¼ 0.0012) and a down-
regulation at 9 months (P ¼ 0.0173) compared with controls (A). Ddit4l was down-regulated in YAC128 compared with controls at 6 months (P ¼ 0.0079), 9
months (P ¼ 0.030) and 24 months (P ¼ 0.014) (B). Gsg1l was only down-regulated in YAC128 at 24 months of age compared with controls (P ¼ 0.018) (C).
Slc45a3 showed up-regulation at 9 months (P ¼ 0.029), 12 months (P ¼ 0.0087) and 24 months (P ¼ 0.0152) in YAC128 compared with controls (D). In
addition toWt1, DAZ interacting protein 1-like (Dzip1l) and retrotransposon gag domain containing 4 (Rgag4) were identified on the Illumina platform as differ-
entially expressed at 24 months of age. YAC128 showed down-regulation of Dzip1l at 6 months (P ¼ 0.0055), 12 months (P ¼ 0.0012) and 24 months
(P ¼ 0.0221) compared with controls (E). Rgag4 was down-regulated in YAC128 compared with controls at 6 months (P ¼ 0.0010) and 24 months
(P ¼ 0.0082) (F). YAC128 data were normalized to the calculated average for the wild-type controls for each individual target and time point. The bars
show the mean+SEM for each target. Statistical analysis was performed using Mann–Whitney two-tailed U-test; P, 0.05; P, 0.01; P, 0.001.
White and grey bars indicate wild-type controls and YAC128, respectively.
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controls displayed similar transcript levels (P ¼ 0.0079 in
6 months; P ¼ 0.030 in 9 months; P ¼ 0.014 in 24 months
YAC128 versus controls). Gsg1l was only down-regulated in
YAC128 at 24 months of age (P ¼ 0.018; Fig. 1C). In contrast,
Slc45a3 was up-regulated almost 3-fold in the YAC128 mice
compared with controls at 9 months of age and continuously
up-regulated at later time points (P ¼ 0.029 in 9 months;
P ¼ 0.0087 in 12 months; P ¼ 0.015 in 24 months YAC128
versus controls; Fig. 1D). Transcriptional expression profiles
with down-regulation in YAC128 compared with controls
were observed for Dzip1l (P ¼ 0.0055 in 6 months;
P ¼ 0.0012 in 12 months; P ¼ 0.022 in 24 months YAC128
versus controls; Fig. 1E) and Rgag4 (P ¼ 0.0010 in 6
months; P ¼ 0.0082 in 24 months YAC128 versus controls;
Fig. 1F). For the genes obtained from the combined ranking
lists, YAC128 mice showed a significant up-regulation of
Pcdh20 at all time points, except for at 6 months (P ¼ 0.018
at 3 months; P ¼ 0.017 at 9 months; P ¼ 0.0012 at 12
months; P ¼ 0.035 at 24 months YAC128 versus controls;
Fig. 2A). Sfmbt2, Acy3 and Polr2a showed up-regulation at
the two late-stage time points in YAC128 compared with con-
trols; Sfmbt2 (P ¼ 0.0012 for both 12 and 24 months YAC128
versus controls; Fig. 2B); Acy3 (P ¼ 0.0025 for 12 months;
P ¼ 0.0012 for 24 months YAC128 versus controls; Fig. 2C);
Polr2a (P ¼ 0.035 for 12 months; P ¼ 0.0047 for 24 months
YAC128 versus controls; Fig. 2D). In addition, there were
trends toward differential expression for several RNA targets
at individual time points even though statistical significance
was not reached. Acy3 (P ¼ 0.055; Fig. 2C) and Polr2a
(P ¼ 0.051; Fig. 2D) showed borderline significance for
up-regulation in 9-month-old YAC128 compared with controls.
Several of the analyzed target genes displayed a significant
difference in transcriptional expression at the earlier time
points. Actn2 was down-regulated in YAC128 as early as
3 months and consistently until 24 months of age (P ¼
0.0040 in 3 months; P ¼ 0.036 in 6 months; P ¼ 0.0087 in
9 months; P ¼ 0.0012 in 12 months; P ¼ 0.014 in 24-month-
old YAC128 versus controls; Fig. 3A). This was the only
gene that showed a significant differential expression at every
time point analyzed. Ddah1 showed a 5-fold down-regulation
in the YAC128 compared with controls at 24 months in
addition to changes observed at earlier time points (P ¼
0.025 for 6 months; P ¼ 0.022 for 12 months; P ¼ 0.0020 for
24-month-old YAC128 versus controls; Fig. 3B). Ppp1r9a
Figure 2. Time course analysis of differentially expressed genes identified using the combined rank list for 24-month-old YAC128 and controls. We analyzed the
top 10 genes from the established combined rank list. YAC128 and wild-type littermate controls were analyzed at 3, 6, 9, 12 and 24 months of age by qPCR. In
addition toWt1 and Ddit4l, we analyzed Protocadherin 20 (Pcdh20), Scm-like with four mbt domains 2 (Sfmbt2), aspartoacylase 3 (Acy3) and polymerase (RNA)
II (DNA directed) polypeptide A (Polr2a) that were included in the top 10 genes of the combined rank list for 24-month-old mice. Pcdh20 was up-regulated in
YAC128 compared with controls at 3 months (P ¼ 0.0186), 9 months (P ¼ 0.0173), 12 months (P ¼ 0.0012) and 24 months (P ¼ 0.035) (A). Sfmbt2 was
up-regulated in YAC128 compared with controls at 12 months (P ¼ 0.0012) and 24 months (P ¼ 0.0012) (B). Acy3 was up-regulated at 12 months
(P ¼ 0.0025) and 24 months (P ¼ 0.0012) (C). There was a tendency for increase of Acy3 transcript levels also at 9 months (P ¼ 0.056). Polr2a transcript
levels were increased in YAC128 at 12 months (P ¼ 0.035) and 24 months (P ¼ 0.0047) (D). YAC128 data were normalized to the calculated average for
the wild-type controls for each individual target and time point. The bars show the mean+SEM for each target. Statistical analysis was performed using
Mann–Whitney two-tailed U-test; P , 0.05; P , 0.01; P , 0.001. White and grey bars indicate wild-type controls and YAC128, respectively.
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showed a down-regulation in YAC128 compared with controls
at the two late-stage time points (P ¼ 0.0047 for 12 months;
P ¼ 0.0012 for 24 months YAC128 versus controls; Fig. 3C).
In general, the Affymetrix platform gave a better estimate
than Illumina, of the magnitude of fold change based on our
qPCR results (Table 2).
Transcriptional alterations in HD cases are concordant
with changes observed in YAC128
We next studied the genes that were differentially expressed in
mouse striatum in caudate samples from human HD and control
brains. In total, we analyzed 14 genes that were identified to be
differentially expressed on the individual platforms, Affymetrix
and Illumina, and the combined rank lists for 12-month and
24-month data, respectively. WT1 showed a tendency for
up-regulation inHD caudate, but did not reach statistical signifi-
cance (P ¼ 0.082, Mann–Whitney two-tailed U-test; Fig. 4A).
This tendency to up-regulation was concordant to observations
in YAC128 compared with controls at 3, 12 and 24 months of
age (Table 2). We decided to analyze DMPK expression in
human HD cases, since DMPK showed borderline significance
for down-regulation in 24-month-old YAC128 mice compared
with controls. However, in our analysis,DMPK showed no tran-
scriptional changes in human HD cases (Fig. 4C). GSG1L
showed down-regulation in HD caudate with borderline signifi-
cance (P ¼ 0.051; Fig. 4D). The gene expression profile was
concordant with the YAC128 profile at 24 months of age.
SLC45A3 was highly up-regulated in HD caudate compared
with controls (P ¼ 0.0043; Fig. 4E), concordant with the
expression profile in YAC128 mice compared with controls at
9, 12 and 24 months of age. DDIT4L (Fig. 4B), DZIP1L
(Fig. 4F) and RGAG4 (Fig. 4G) did not show any significant
changes in HD caudate versus controls. We also studied the
additional genes that were identified as differentially expressed
from the combined rank lists for the 12- and 24-month YAC128
data sets. PCDH20 was down-regulated in HD caudate com-
pared with controls (P ¼ 0.0043; Fig. 5A). This expression
profile was discordant to the changes observed in the
YAC128 and controls. SFMTB2, ACY3 and POLR2A
(Fig. 5B–D) did not show any significant transcriptional
changes between HD cases and controls. All three genes ana-
lyzed from the combined rank list created from the 12-month
data and validated to be differentially expressed in YAC128
and controls also showed transcriptional changes in human
HD caudate samples: ACTN2 (P ¼ 0.017; Fig. 5E), PPP1R9A
(P ¼ 0.017; Fig. 5F) and DDAH1 (P ¼ 0.017; Fig. 5G).
ACTN2 and PPP1R9A showed down-regulation, whereas
DDAH1 showed up-regulation in HD case caudate compared
with controls. Gene expression profiles for ACTN2 and
PPP1R9A were both concordant with observations in theFigure 3. Time course analysis of differentially expressed genes identified
using the combined rank list for 12-month-old YAC128 and controls. We ana-
lyzed the top 10 genes from the established combined rank list. YAC128 and
wild-type littermate controls were analyzed at 3, 6, 9, 12 and 24 months of age
by qPCR. We analyzed actinin alpha 2 (Actn2), dimethylarginine dimethyla-
minohydrolase 1 (Ddah1) and protein phosphotase 1, regulatory (inhibitor)
subunit 9A (Ppp1r9a). Actn2 was down-regulated in YAC128 compared
with controls at all five time points; at 3 months (P ¼ 0.0040), 6 months
(P ¼ 0.036), 9 months (P ¼ 0.0087), 12 months (P ¼ 0.0012) and 24
months (P ¼ 0.014) (A). Ddah1 transcript levels were lower in YAC128 com-
pared with controls at 6 months (P ¼ 0.021), 12 months (P ¼ 0.022) and 24
months (P ¼ 0.0012) (B). Ppp1r9a was down-regulated in YAC128 compared
with controls at 12 months (P ¼ 0.0047) and 24 months (P ¼ 0.0012) (C).
YAC128 data were normalized to the calculated average for the wild-type con-
trols for each individual target and time point. The bars show the mean+
SEM for each target. Statistical analysis was performed using Mann–
Whitney two-tailed U-test; P , 0.05; P , 0.01; P , 0.001. White and
grey bars indicate wild-type controls and YAC128, respectively.
Human Molecular Genetics, 2010, Vol. 19, No. 8 1443
YAC128 data, in contrast toDDAH1which was up-regulated in
HD caudate and down-regulated in YAC128 at 6, 12 and 24
months compared with controls.
DISCUSSION
We performed genome-wide expression profiling on striatal
tissue from YAC128 and controls at 12 and 24 months of
age. We utilized two powerful platforms in parallel, Illumina
and Affymetrix arrays, with the ultimate goal to study tran-
scriptional changes in striatum and to identify genes of impor-
tance for disease pathogenesis. We identified 13 genes that
were differentially expressed in YAC128 compared with con-
trols, as confirmed in independent groups of YAC128 samples.
We also used qPCR to further assess time-dependent altera-
tions in the expression of these genes with respect to the
onset and progression of disease phenotype. Most importantly,
we studied these genes in HD cases and we showed transcrip-
tional alterations consistent with the findings in YAC128.
Transcriptional changes identified may derive from a variety
of different mechanisms involved in disease and may therefore
lead to the identification of crucial pathways involved in HD
pathogenesis.
It was first shown that long polyglutamine stretches activate
transcription in vitro (25,26) and many transcription factors
contain glutamine-rich activation domains such as CREB-
binding protein (CBP), TATA-box binding protein (TBP)
and specificity protein 1 (Sp1). Accordingly, mutant hunting-
tin protein has been suggested to act directly as a transcription
factor by mimicking or interfering with the actions of tran-
scription factors that contain glutamine-rich activation
domains (27). More recent studies showed that huntingtin
protein, both wild-type and mutant, has the ability to bind
DNA without additional transcription factors (28). Mutant
huntingtin, however, increased the transcriptional binding
factor activity overall. In addition, mutant huntingtin displayed
increased occupancy at gene promoters in vivo compared
with wild-type huntingtin. Mutant huntingtin is thus suggested
to alter the transcriptional profile through modulation of
the DNA confirmation and altered binding of transcriptional
factors (28).
Several studies indicate that mutant huntingtin interacts
with sequesters and/or compromises the normal function of
transcription factors such as Sp1 (29,30), the nuclear receptor
co-repressor (N-CoR) (31), CBP (32,33), p53 (34,35), TBP
(36) and TAFII130 (37) or disrupts the core transcriptional
machinery by interacting with the pre-initiation complex
(38). Furthermore, studies have provided evidence that hun-
tingtin may modulate chromatin structure by interfering with
the acetylated and deacetylated states of histones, which led
to the testing of HDAC inhibitors for therapeutic intervention
in HD. It has also been suggested that intranuclear inclusions
may non-specifically alter gene expression by reducing the
association of transcription factors to DNA binding sites
(39), although this was shown not to be the case in the R6/2
mouse model of HD (40).
Previously, Kuhn et al. (12) performed a meta-analysis on
seven different mouse models of HD and human postmortem
caudate. In this study, it was concluded that short N-terminal
mouse models exhibit rapid effects and transcriptional
changes similar to what is observed in human brain. Neverthe-
less, knock-in (CHL2Q150/Q150, HdhQ92/Q92) and the YAC128
transgenic full-length huntingtin mouse models also displayed
significant HD-like transcript profiles at an older age. No
distinct transcriptional changes could be assigned to the
differences in expression of full-length huntingtin and
Table 2. Summary of expressional profiling and transcriptional alterations in YAC128 and HD cases
Gene
symbol
YAC128
Affy
P-value
YAC128
Affy FCa
YAC128
Illumina
P-value
YAC128
Illumina
FCa
YAC128
qPCRb
qPCR
FCa,c
Human
Affy
P-valued
Human
Affy
FCd
Human
qPCRe 
YAC128 versus
human HD
concordance
Wt1f 2.1E206 0.76 1.5E204 0.20 3,12,24 9 2.4 1.2E203 20.12 P ¼ 0.08 –
Ddit4lf 2.9E206 21.2 3.3E202 20.39 6,9,24 21.2 7.0E203 20.23 P ¼ 0.66 –
Gsg1lf 1.5E205 20.53 2.8 E201 20.029 24 20.79 4.0E203 20.098 P ¼ 0.052 Yes
Scl45a3f 1.0E204 1.1 9.3E202 0.13 9,12,24 0.53 1.1E202 0.17 P ¼ 0.004 Yes
Dzip1lf 5.8E201 0.13 5.4E204 20.053 6,12,24 20.34 3.6E202 0.083 P ¼ 0.13 –
Rgag4f 3.7E201 20.30 1.1E203 20.16 6,24 20.46 NA NA ND –
Pcdh20f 3.0E204 1.1 8.5E203 0.11 3,9,12,24 0.50 2.5E207 20.71 P ¼ 0.004 No
Sfmbt2f 3.5E203 0.84 1.4E203 0.062 12,24 1.2 6.4E201 20.02 P ¼ 0.08 –
Acy3f 4.8E203 0.96 1.1E203 0.25 12,24 1.4 6.2E201 20.02 P ¼ 0.33 –
Polr2af 1.8E203 0.53 2.5E202 0.18 12,24 0.75 5.8E201 0.03 P ¼ 0.13 –
Actn2g 1.0E202 20.69 2.8E204 20.50 3,6,9,12,24 20.90 5.4E211 20.78 P ¼ 0.017 Yes
Ddah1g 1.6E202 20.29 6.3E201 20.058 6,12,24 20.28 2.2E206 0.45 P ¼ 0.017 No
Ppp1r9ag 1.8E202 21.4 1.0E202 20.26 12,24 20.34 8.1E209 20.66 P ¼ 0.017 Yes
ND, not determined; NA, not assigned.
aFold change (FC) is shown as log2 transformed values. Positive values indicate up-regulation in YAC128 compared to controls; Negative values indicate
down-regulation in YAC128 compared to controls.
bArrows indicate up or down-regulation of significant transcriptional changes in YAC128 compared to controls at different ages indicated in months.
cFold change indicated shows the magnitude of transcriptional change (log2 transformed) observed with qPCR for 24 month old YAC128 compared to control mice
and 12 month old mice for Actn2, Ddah1 and Ppp1r9a.
dHuman HD gene expression data has been previously published in Hodges et al. 2006 (10). Fold change (FC) is shown as log2 transformed values.
eArrows indicate up- or down-regulation of significant transcriptional changes in HD caudate samples compared to controls.
fP-values and fold change data (FC) for Affymetrix and Illumina results are from data set comparing YAC128 and controls at 24 months of age.
gP-values and fold change data (FC) for Affymetrix and Illumina results are from data set comparing YAC128 and controls at 12 months of age.
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Figure 4. Transcriptional alterations identified in human HD caudate compared with controls. We analyzed the genes identified as differentially expressed in the
YAC128 transgenic model when validating the results from the individual platforms: Affymetrix and Illumina. We quantified WT1, DDIT4L, DMPK, GSG1L,
SLC45A3, DZIP1L and RGAG4 in human HD caudate (n ¼ 6) and controls (n ¼ 5) by qPCR. WT1 (A), DDIT4L (B) and DZIP1L (F) did not show differential
expression, although showing trends for up-regulation of WT1 and DZIP1L in HD cases compared with controls. GSG1L showed down-regulation in HD caudate
with borderline significance (P ¼ 0.051) (D), whereas SLC45A3 was up-regulated in HD cases compared with controls (P ¼ 0.0043) (E). RGAG4 did not show
any differential expression between HD cases and controls (G). The middle line of the Box and Whisker plot shows the median, the top and bottom lines show
the 75th and 25th percentile, respectively. The top and bottom Whiskers indicate the largest and smallest values. Statistical analysis was performed using Mann–
Whitney two-tailed U-test; P , 0.05; P , 0.01; P , 0.001.
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Figure 5. Transcriptional alterations identified in human HD caudate compared with controls. We analyzed the genes identified as differentially expressed in the
YAC128 transgenic mice when validating results from the established 12- and 24-month combined rank lists. In addition to WT1 and DDIT4L, we analyzed
PCDH20, SFMBT2, ACY3 and POLR2A mRNA expression in human caudate of HD cases and controls by qPCR. These genes were initially identified to be
differentially expressed in the YAC128 compared with controls when validating genes from the combined rank list for 24-month-old mice. PCDH20 was down-
regulated in HD cases compared with controls (P ¼ 0.0043) (A). SFMBT2 (B), ACY3 (C) and POLR2A (D) were not differentially expressed in HD cases com-
pared with controls, although SFMBT2 and ACY3 showed tendencies for up-regulation in HD cases compared with controls. We also analyzed ACTN2, DDAH1
and PPP1R9A mRNA expression in human caudate of HD cases and controls. These genes were initially identified to be differentially expressed in the YAC128
compared with controls when validating genes from the combined rank list for 12-month-old mice. All three genes showed transcriptional changes. ACTN2 (E)
and PPP1R9A (F) were both down-regulated in HD cases compared with controls (P ¼ 0.017), whereas DDAH1 (G) was up-regulated in HD cases compared
with controls (P ¼ 0.017). The middle line of the Box and Whisker plot shows the median, the top and bottom lines show the 75th and 25th percentile, respect-
ively. The top and bottom Whiskers indicate the largest and smallest values. Statistical analysis was performed using Mann–Whitney two-tailed U-test;
P , 0.05; P , 0.01; P , 0.001.
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N-terminal huntingtin fragments (12). Polyglutamine diseases
share many features including a polyQ-dependent neurodegen-
eration and inclusion body pathology (41,42). Transcriptional
alterations observed could thus be caused by the polygluta-
mine expansion alone and be independent of the huntingtin
protein context (15). Moreover, the transcriptional changes
observed may be due to secondary bystander effects from
affected tissue as well as surrounding tissue, and/or changes
not related to disease. Regardless, transcriptional dysregula-
tion may be an important mechanism in HD pathogenesis.
Several genome-wide expression studies have been performed
and it has been difficult to extrapolate what changes are rel-
evant to disease pathogenesis. We validated that Wt1,
Ddit4l, Gsg1l, Slc45a3, Dzip1l and Rgag4, which were
initially identified on either the Affymetrix or Illumina plat-
form, were differentially expressed. Remarkably, by combin-
ing the results from the Affymetrix and Illumina arrays we
were able to pinpoint additional genes that were differentially
expressed. These genes were Pcdh20, Sfmbt2, Acy3, Polr2a,
Ddah1, Actn2 and Pppr1r9a. This is partly due to the down-
weighting of false-positive results (reduction of Type I error)
when combining the two data sets, but more notably, this
approach helped in eluting genes of interest despite small
sample sizes and low magnitude of transcriptional changes
in our experimental setting.
In our study, we showed transcriptional changes for selected
genes in our YAC128 mouse model of HD already at 3 months
of age. This indicates that the changes observed inWt1, Pcdh20
and Actn2might play an important role in disease pathogenesis,
since neuropathological changes are not manifested at this early
time point. Interestingly,Wt1 displayed transcriptional changes
with some distinct fluctuations observed throughout the time
points measured, whereas Actn2 was consistently down-
regulated in YAC128 compared with controls. In contrast, the
alterations in Ppp1r9a, which show late transcriptional
changes from 12 months on, may reflect a secondary response
to neuronal loss and additional bystander effects from both
affected as well as adjacent brain regions.
We studied the gene expression of several genes in HD
cases and controls and showed transcriptional changes in
SLC45A3, PCDH20, ACTN2, DDAH1 and PPP1R9A. The
genes showing a differential transcriptional expression
profile in YAC128 and controls, but not reaching statistical
significance in human samples, might still be involved in
HD pathogenesis. In our study, discrepancies in transcriptional
expression profiles between the YAC128 mouse and human
HD case data might be due to biological inter-variability in
the human samples. The HD grades analyzed ranged from
1 to 3 in the human samples, which might reduce the power
to detect differences due to sample variability. In addition,
differences in the postmortem interval might have an effect
on the expression of some genes together with general biologi-
cal variability in the samples analyzed (43,44).
Several of the genes we have identified to be differentially
expressed are suggested to be involved in RNA regulation, i.e.
Wt1, Dzip1l, Sfmbt2 and Polr2a. The gene encoding fused in
sarcoma (FUS) was recently linked to amyotrophic lateral
sclerosis (ALS) and shown to be involved in RNA regulation
(45,46). This discovery is an example of neurodegenerative
disease caused by a mutation in a gene that is predominantly
involved in DNA repair, and regulation of RNA transcription,
splicing and transport.
Wilm’s tumor 1 homolog (Wt1) plays an essential role in the
normal development of the urogenital system, and the human
gene is mutated in a small subset of patients with Wilm’s
tumors (47).Wt1 belongs to a family of zinc-finger transcription
factors for which a-actinin 1 (Actn1) has been identified as an
mRNA target (48).The WT1(þKTS) isoform is suggested to
bind close to or at the start codon of Actn1 mRNA (48). More
recently, it was shown that WT1 associated with transcripts
encoding actin-binding proteins and other cytoskeletal proteins
including a-actinins and Ppp1r9a (49). We performed a
sequence comparison of the region around the transcriptional
start site for murine Actn1 and Actn2 (data not shown). There
was 70% homology between these regions, suggesting Wt1
could potentially act as a transcription factor involved in
Actn2 regulation. Additional experiments are required to
study putative interactions and to confirm whetherWt1 directly
regulates Actn2 and Ppp1r9a. Wt1 mRNA was in low abun-
dance compared with Actn2 in the striatum of YAC128 and
control mice. We observed a significant reduction of Actn2
mRNA levels at all time points measured compared with
levels at 3 months in both YAC128 and controls (data not
shown). Apart from this observation, there is no obvious corre-
lation in the expression profiles of Wt1 and Actn2 in the
YAC128 or control mice. Transcript levels in human HD
caudate showed a tendency for up-regulation in HD cases com-
pared with controls, which correlates to increased levels
observed in the YAC128 mice at 3, 12 and 24 months of age.
This concordance strengthens the hypothesis that WT1 may
play an important role in HD pathogenesis.
Actn2 was found to be down-regulated in YAC128 mice
compared with controls as early as 3 months of age. This
gene displays a consistent down-regulation at all time points
analyzed. More importantly, this down-regulation was con-
firmed in human HD caudate. Our findings in YAC128 mice
and HD patients are in agreement with observations made in
R6/2 mice both at 6 and 12 weeks of age, in R6/1 mice and
in previous analysis of human HD samples (9,10,14). Actn2
is involved in cell adhesion and cytoskeletal arrangement
and has been suggested to play a crucial role for the anchoring
of NMDA receptors in central neurons (50–52). It has pre-
viously been shown that Actn2 co-immunoprecipitates with
the protein RGS9-2 in rat striatum, suggesting a functional
relationship between RGS9-2 and a-actinin 2 in calcium-
mediated inactivation of NMDA receptors (53).
Slc45a3 belongs to a family of solute carriers with over 25
members. Slc14a1, which belongs to this same family, has
previously been shown to be differentially expressed both in
human HD caudate (10) as well as in the R6/2 model (54).
We observed up-regulation of Slc45a3 in YAC128 at 9, 12
and 24 months of age as well as in HD caudate compared
with controls. The protein is predicted to be a plasma mem-
brane protein and has been shown to constitute the majority
of erythroblast transformation-specific family member gene
fusions observed in prostate cancers. Slc45a3 gene expression
is not unique to prostate tissue and may play an important role
in solute regulation in striatal neurons (55).
Protocadherin 20 (Pcdh20) belongs to the cadherin super-
family, of which most members are expressed predominantly
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in the central nervous system. Protocadherins are involved in
Ca2þ-mediated cell–cell adhesion and are suggested to be
involved in the formation and maintenance of synaptic con-
nections. In situ hybridization studies performed on rat brain
during early postnatal stage (P3), a critical period for estab-
lishment of specific synaptic connections, provide evidence
for region-dependent expression patterns in cerebral cortex
of several protocadherins, including Pcdh20 (56). Data
suggest that there is a correlation between regional expression
patterns of different protocadherins and development of
specific synaptic connections between cerebral cortex and
other communicating brains regions (56). YAC128 exhibited
an up-regulation of Pcdh20 as early as 3 months of age and
also at 9, 12 and 24 months, while we observed a down-
regulation of PCDH20 in the caudate of HD cases compared
with controls. This data suggests that alterations in Pcdh20
expression may lead to impairment of synaptic connections
in striatum.
Dimethylarginine dimethylaminohydrolase 1 (Ddah1) is
one of two described enzymes (Ddah1 and Ddah2) that hydro-
lyzes methylated arginine analogues and asymmetric dimethy-
larginine (ADMA) produced during cellular turnover of
methylated proteins. ADMA is an endogenous inhibitor of
nitric oxide synthase (NOS), which catalyzes NO production
(57,58). Thus, Ddah1 is a target for novel therapeutic agents
designed to modulate NO generation. Neuronal nitric-oxide
synthase-positive interneurons constitute 10% of the cells
in the striatum. These interneurons persist in HD, in contrast
to the GABAergic medium spiny neurons (MSNs) which are
susceptible to neurodegeneration in the striatum. In one
study, it was hypothesized that NO nitrosylates the NMDA
receptors in the interneurons and render them less sensitive
to activation, whereas NO diffusing into the MSNs lead to tox-
icity when it reacts with superoxide anion (O2
2) (59,60).
Administration of NOS inhibitors in R6/2 transgenic mice
accelerated the onset of disease symptoms (61). R6/1 trans-
genic mice with only one copy of nNOS showed a delayed
onset of disease, whereas mice lacking both copies displayed
an acceleration of the disease (61). We showed decreased
levels of Ddah1 in YAC128 compared with controls which
might cause decreased hydrolysis of ADMA, and reduced
inhibition of nitric oxide synthase (NOS), resulting in
increased levels of NO in the YAC128. We observed increased
levels of DDAH1 in HD cases which might suggest an
up-regulation of the enzyme to compensate for reduced
levels of NO production due to increased levels of ADMA
in the brain. Alternatively, increased DDAH1 levels might
be a primary or secondary contributor to the pathological
state of HD. We need to further investigate the relationship
between DDAH1, ADMA, NOS and NO and the potential
role these molecular targets might play in HD pathogenesis.
PPP1R9A [protein phosphatase 1, regulatory (inhibitor)
subunit 9A] encodes Neurabin I (neural tissue-specific
F-actin-binding protein I) whose name stems from the fact
that Neurabin I has been shown to bind and inhibit the func-
tion of protein phosphatase I (PPI) (62,63). In human,
PPP1R9A is located in a cluster of imprinted genes and the
protein has been shown to be involved in actin cytoskeleton
dynamics and in synaptic formation and function (63,64). It
has been shown that Ppp1r9a is imprinted mainly in skeletal
muscle (maternally expressed), but not in brain (64). Further-
more, it has also been shown that Neurabin I is highly concen-
trated in the synapses of developed neurons and is involved in
neurite formation (65). We showed a down-regulation of
Ppp1r9a in striatum in YAC128 mice as well as HD cases
compared with controls. Down-regulation of both Ppp1r9a
and Actn2 strengthens the evidence that deficiencies in cyto-
skeletal dynamics play a role in HD pathogenesis.
We have identified protocadherin 20 (Pcdh20), neurabin I
(Ppp1r9a) and actinin alpha 2 (Actn2) to be transcriptionally
altered in the striatum of the YAC128 mice and in human
HD caudate. These genes are known to play a role in synaptic
formation, synaptic plasticity and cytoskeletal arrangement.
Both Actn2 and Pcdh20 were altered already at 3 months in
the YAC128 mice. Our results suggest that transcriptional
changes of these genes reflect neuronal dysfunction of path-
ways involved in axonal transport, synaptic plasticity and den-
drite integrity. The hallmark of HD is selective degeneration
of vulnerable medium spiny neurons, whereas interneurons
are spared in the striatum. Prior to cell death, however, there
are neuropathological changes occurring that indicate early
synaptic pathology. Morphological changes, including dys-
trophic neurites, have been described in spiny striatal and cor-
tical pyramidal neurons in HD (66–68). HD mice have been
employed to study the correlation between dysmorphic
changes in neurons and behavioural abnormalities. Dys-
morphic dendrites in the striatal spiny and the cortical pyrami-
dal neurons were shown to be predictive of onset and severity
of behavioural deficits in HD mice (69). Dystrophic neurites
have been suggested to correlate with alterations in synaptic
plasticity in HD. For example, the R6/2 mice exhibit altered
synaptic plasticity, which has been suggested to contribute
to the pre-symptomatic changes in cognition (70). Further-
more, both YAC46 and YAC72 HD mice exhibit early electro-
physiological abnormalities indicative of altered synaptic
function, including excitatory NMDA receptor activity
(16,71). It has been suggested that cell–cell interactions
between cortical and striatal neurons are critical for HD patho-
genesis through the study of BAC transgenic mice (72). In
addition, mutant huntingtin has been shown to inhibit both
fast axonal transport and elongation of neuritic processes
(73). We present novel transcriptional changes in several
genes that are involved in synaptic integrity and function.
The finding that these genes are transcriptionally dysregulated
in the YAC128 mice and human HD caudate emphasizes the
importance of these pathways in HD pathogenesis. Moreover,
modulation of synaptic influences may have therapeutic poten-
tial in HD.
In our study, we have identified several genes that are dif-
ferentially expressed in both the YAC128 model as well as
in human HD caudate. Transcriptional changes identified in
this study might reflect: (1) genes that lie within the patho-
genic pathways leading to neurodegeneration; (2) genes that
reflect the cellular attempts to block the disease process; and
(3) genes that reflect non-specific responses to neurodegenera-
tion. The first group of genes will provide novel insights into
the specific downstream mechanisms of neurodegeneration.
Knowledge of these pathways will provide new experimental
starting points from which to discover novel approaches
directed specifically to modify these disease-causing pathways
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in HD. The second group of genes represents components of
pathways that are up- or down-regulated in an attempt to
reduce neuronal death. These might be exploited in the
future as a way to protect neurons. The profiling of YAC128
mice has illuminated several molecular changes in HD brain
that have received little or no attention in previous studies.
Transcriptional changes are likely to be important in HD
pathogenesis. Full-length models have less obvious transcrip-
tional changes than HD fragment models as described pre-
viously (74). Nevertheless, in this paper, we present an
experimental approach that has successfully identified novel
transcriptional changes in YAC128 striatum and human HD
caudate that have been validated by qPCR. Additional
studies can be envisaged to better understand the contribution
of these genes and their potential role in HD pathogenesis.
Ultimately, further characterization of the role of these genes
may lead to the identification of new pathways involved
in HD.
MATERIALS AND METHODS
Mice
Transgenic HD mice expressing human HD huntingtin with
120 CAG repeats (YAC128) and wild-type littermates were
used for the described experiments (18). The mice were
group housed in polystyrene cages under a normal light–
dark cycle (6 am to 8 pm) in a clean facility and with free
access to water and standard rodent chow. All experiments
were performed in accordance with the University of British
Columbia animal care committee.
RNA isolation for genome-wide expression analysis using
the Affymetrix and Illumina platforms
Striatal tissue was collected from 12- and 24-month-old
YAC128 mice and wild-type littermates. Animals were anaes-
thetized using Avertine, and tissue was collected in RNAlater
(Ambion) and stored at 2808C prior to RNA isolation. Hom-
ogenization of tissue was performed using a Fastprep Hom-
ogenizer (ThermoScientific). Total RNA from mouse
striatum was extracted using the Qiagen RNeasy mini kit
and eluted in 30 ml RNase free water according to the manu-
facturer’s instructions. For 12-month-old mice, total RNA
from four YAC128 and four wild-type littermates was
extracted. For 24-month-old mice, total RNA from six
YAC128 and four wild-type littermates was extracted. Total
RNA was quantified using the Nanodrop spectrophotometer
(ThermoScientific) and the integrity of the total RNA was
determined electrophoretically on the RNA Nano Assay
Chip run on the Bioanalyzer 2100 (Agilent Tech).
Illumina Bead arrays
Biotinylated antisense RNA was generated using the Illumina
Totalprep RNA amplification kit (Illuminaw) and hybridized
to an Illumina Sentrixw Mouse-6 sample BeadChip (Illumi-
naw). The BeadChip used contained six arrays and interro-
gated 47 769 transcripts derived from the National Center
for Biotechnology Information (NCBI) Reference Sequence
(RefSeq) database, the RIKENw FANTOMTM2 database and
the Mouse Exonic Evidence Based Oligonucleotide
(MEEBO) set. The BeadChips were scanned on the Bead
express platform (Illuminaw) and gene expression analysis
was undertaken using the Illumina BeadStudio software (Illu-
minaw).
Affymetrix
RNA was prepared according to the manufacturer’s two-cycle
target labeling procedure (Affymetrix, Inc.) with a starting
amount of 25 ng of total RNA per sample. We used the
Mouse Genome 430 2.0 Arrays (Affymetrix, Inc.) for all
samples. This mouse array is a single GeneChip comprising
over 45 000 probe sets representing more than 34 000 well-
substantiated mouse genes.
Statistical analysis of Illumina and Affymetrix
genome-wide expression data
Quality assessment was performed using the affy R package
(75). Pre-processing of the Illumina and Affymetrix microar-
rays was done using Bead array (76) and Affymetrix Gene-
Chipw Operating Software (GCOS), respectively. In the
analysis, the data was split into two based on age, 12 and 24
months, respectively. Chips were normalized using Robust
Multiarray Average (RMA). Within each subset, we per-
formed a t-test between the wild-type and transgenic
YAC128 data. The genes were ranked based on P-values
and assigned to probes using Gemma (22) and Illumina and
Affymetrix provided annotations. These ranks were sub-
sequently used to create the combined rank list described.
We calculated the combined rank for each target by averaging
the individual ranks on the Affymetrix and the Illumina plat-
forms, creating a new gene list based on the calculated com-
bined rank value obtained. Corrections for multiple testing
were performed using the false discovery rate according to
Benjamini and Hochberg (21,77).
Human material
RNA was extracted from fresh-frozen samples (stored in
2808C) of human caudate collected with minimal postmortem
interval to autopsy from six HD-gene-positive cases and five
age- and sex-matched controls as described previously (10).
All samples were carefully selected on the basis of RNA
quality, and the HD cases were additionally graded according
to the Vonsattel grade of disease pathology (scale 0–4) with
two samples each representing HD grade 1, 2 and 3, respect-
ively (78). RNA was extracted from human caudate using
TRIzol (Invitrogen) followed by RNeasy column cleanup
(Qiagen) using the manufacturer’s protocols.
Relative quantification of mRNA by qPCR
Tissue samples from striatum were sampled from naı¨ve
YAC128 and wild-type littermates at 3, 6, 9, 12 and 24
months of age, respectively. Striatal tissue from 3-, 6- and
9-month-old samples were frozen immediately at 2808C.
Striatal samples from 12- and 24-month-old mice were
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stored in RNAlater at 2808C. Homogenization of each indi-
vidual tissue was performed using a Fastprep Homogenizer
(ThermoScientific). We isolated total RNA from homogenized
tissues using the Qiagen RNeasy minikit. We carried out
reverse transcription cDNA synthesis using the Quantitect
Reverse Transcription kit (Qiagen) according to the manufac-
turer’s instructions. In total, striatal RNA was extracted from
eight wild-type and five YAC128 mice for 3-month-old
mice; nine wild-type and eight YAC128 mice for 6-month-old
mice; five wild-type and six YAC128 mice for 9-month-old
mice; six wild-type and seven YAC128 mice for 12-month-old
mice; and seven wild-type and six YAC128 mice for
24-month-old mice. Quantitative analyses of mRNA
expression were performed using FastSYBRwgreen mix
according to the manufacturer’s instructions (Applied Biosys-
tems). Amplification of cDNA was performed using the 7500
Fast Real-Time PCR System (Applied Biosystems). Primers
were constructed over exon/exon boundaries to avoid amplifi-
cation of contaminating genomic DNA. All primers were
designed using the Primer Express software version 3.0
(Applied Biosystems). Primer sequences are available as Sup-
plementary Material (Table S3 for mouse and Table S4 for
human qPCR analysis). Relative quantification of mRNA
levels was calculated using the standard curve method, with
amplification of target mRNA and control genes in separate
wells. Standard curves were created using 10-fold serial
dilutions of either mouse liver, cortex or kidney cDNA.
Each sample was run in duplicate. The relative amount of
mRNA in each well was calculated as the ratio between the
target mRNA and a normalization factor calculated from the
endogenous levels of the reference genes analyzed. In
Figures 1–3, each sample ratio was divided by the mean of
the wild-type littermate control samples for each individual
time point. The following targets were analyzed for all five
time points according to above: Wilm’s tumor homolog 1
(Wt1), DNA-damage-inducible transcript 4-like (Ddit4),
germ cell-specific gene 1-like protein (Gsg1l), solute carrier
family 45 member 3 (Slc45a3), DAZ interacting protein
1-like (Dzip1l), retrotransposon gag domain containing 4
(Rgag4), Protocadherin-20 (Pcdh20), Scm-like with four
MBT domains protein 2 (Sfmbt2), aspartoacylase-2 (Aminoa-
cylase3) (Acy3), polymerase (RNA) II (DNA directed)
polypeptide A (Polr2a), actinin alpha-2 (Actn2), dimethylargi-
nine dimethylaminohydrolase 1 (Ddah1) and protein phospha-
tase 1, regulatory (inhibitor) subunit 9A (Ppp1r9a). Genes that
were not annotated or only described as cDNA clones at the
time of analysis were not included in the qRT–PCR analysis
of the top 10 genes. These genes include Dio3os (Affymetrix
rank list) and D830041j17Rik (Illumina rank list) (Supplemen-
tary Material, Fig. S1).
Calculation of normalization factor for qPCR data
We analyzed multiple reference genes for normalization
of the qPCR data; 18S ribosomal RNA (Rn18s), beta-2 micro-
globulin (B2m), glyceraldehyde-3-phosphate dehydrogenase
(Gapdh), actin-beta (Actb), ribosomal protein, large, P0
(Rplp0) and hypoxanthine guanine phosphoribosyl transferase
1 (Hprt1). We applied the GeNorm software analysis for cal-
culation of the most accurate normalization factor for our data
measurements at 3, 6, 9, 12 and 24 months, respectively (79).
The normalization factor (NF) was based on geometric aver-
aging of multiple internal control genes. Calculations were
based on the average expression stability and pairwise vari-
ation analysis using the GeNorm-software (http://medgen
.ugent.be/~jvdesomp/genorm/). Accurate NFs were calculated
based on Gapdh, Rn18s and Rplp0 for 3-month data; Gapdh,
Actb and Hprt1 for 6-, 9-and 24-month data; Rn18s, Actb
and Hprt1 for 12-month data; ACTB, GAPDH and PGK1
(phosphoglycerate kinase 1) for human HD and control
caudate samples.
Statistical analysis
Mann–Whitney two-tailed U-test was performed using Graph-
Pad Prism version 4 for statistical analysis of the mRNA
expression.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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